Skip to main content

Researchers have spent decades breeding better potatoes for chips, and their work isn’t done

EAST LANSING, Mich. (AP) — There’s a surprising amount of science in a bag of potato chips.

Researchers have spent decades developing potatoes for chip makers that can grow in all kinds of climates, avoid diseases and pests, sit in storage for months and still deliver a satisfying crunch. They’ve also kept an eye on consumer trends; a shift to snack-size portions has increased the demand for smaller chipping potatoes, for example.

“The potato industry is dynamic,” said David Douches, a Michigan State University professor who leads the school’s Potato Breeding and Genetics Program. “The needs change, the costs, the pressures that they have, and the markets change. So we have to adapt to that with our varieties.”

Douches has developed five new potato varieties for chips in the the last 15 years. His latest breakthrough is a bioengineered potato that can maintain a proper sugar balance when stored at colder temperatures, which can help keep potatoes from rotting. He is currently growing seeds for commercial testing of the potato, which is not yet on the market.

Douches’ work helps fight world hunger; he has developed disease-resistant varieties for farmers in Nigeria, Kenya, Rwanda and Bangladesh. But he’s also helping U.S. chip makers, grateful snackers and Michigan’s $2.5 billion potato industry. While Idaho leads the U.S. in potato production, Michigan is the top producer of potatoes for chips.

There are around 50 unique potato varieties grown for chips in the U.S. right now, according to the National Chip Program, a cooperative that brings together Michigan State and 11 other university breeding programs with growers, companies that make chips, and the U.S. Department of Agriculture.

Efforts to improve those varieties are constant. The National Chip Program evaluates around 225 new potato varieties each year and selects 100 for further trials, said Tim Rendall, the director of production research at Potatoes USA, a trade group that oversees the chip program.

The close partnership between researchers, farmers and potato chip companies is unusual in the food industry, said Phil Gusmano, the vice president of purchasing at Better Made Snack Foods, which has produced potato chips in Detroit since 1930. Better Made worked closely with Douches when he was developing two of the varieties the company uses now, Gusmano said.

“We were able talk about size profile and different needs that make a really good chip,” Gusmano said. “And the great thing is, they’re willing to listen to what we have to say, because if they put together a potato that doesn’t really meet the needs for the end processor, it doesn’t do them any good.”

Breeding a new type of potato can take up to 15 years, Douches said. The simple potato has a surprisingly complicated genetic structure, with four chromosomes in each cell compared to two in most species, including humans. That makes it harder to predict which traits that cross-bred plants will inherit, he said.

“We’re never able to fix a trait and carry that over to the next generation, so it’s very difficult to find a potato that has all the traits that we want,” Douches said.

Douches became fascinated with potato breeding and genetics while in graduate school. At Michigan State, he focuses on chipping potatoes, since Michigan is a leading producer. Around 70% of the state’s potato crop is destined for chip processing, according to the Michigan Ag Council. The trade group estimates that one of every four bags of potato chips produced in the U.S. contains Michigan potatoes.

Breeding potatoes that can sit in storage for nearly a year has been one of the biggest challenges in Douches’ 40-year career. Historically, farmers harvested potatoes and then stored them in huge piles at around 50 degrees Fahrenheit (10 degrees Celsius). Temperatures any colder cause sugar levels to rise in the root vegetables, and higher sugar content leads to darker potato chips. But warmer storage conditions can lead to rot.

“You think they’re just these inanimate objects, but they actually are respiring and breathing,” Douches said. “When you do that to them, you’ve got, like, a two- to three-day window where they’re happy.”

His Manistee variety, which was released in 2013, can be safely stored until July at 45 F (7.2 C) degrees. His new bioengineered potato can be stored at 40 F (4.4 C).

Gusmano said Better Made used to source potatoes from outside of Michigan for half the year because the Michigan potatoes it harvested in the fall only could be stored until February. The company now uses newer varieties, like Douches’ Mackinaw potato, which can be stored until July and is resistant to several common diseases.

“We’re not shipping potatoes from all over the country to be fried here in Michigan,” Gusmano said. “Instead, they’re being shipped from an hour and a half away all year long.”

When you have advanced prostate cancer: What living with the disease looks like

(CNN) — “How long do I have to live ?”When I tell a patient he has prostate cancer, this is usually what he asks me first.With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — expect a five-year relative survival rate of greater than 99% with treatment. Simply put, most men will not die from low-grade prostate cancer.However, once the cancer has spread outside the prostate to the bones and other organs the answer becomes more difficult. Treatment has changed dramatically over the past decade for advanced prostate cancer. New drugs, better imaging and the earlier use of combined therapies are helping men live longer.In a video released July 15, former President Joe Biden gave an update on his prostate cancer, saying he was receiving treatments that have been going well. In May 2025, Biden officially announced that he had an aggressive form of prostate cancer that had spread to his bones. Since then, based on official updates, he has continued hormone therapy, completed a course of radiation and maintained a public presence.His diagnosis brought renewed attention to prostate cancer screening and treatment. Now, more than a year later, his cancer journey offers an opportunity to examine what has changed in the treatment of advanced prostate cancer — and the hope these offer men living with the disease.I recently saw a patient who was diagnosed three years ago with cancer that had already spread to multiple areas in his bones. Since then, he has taken cruises, traveled with his family and spent weekends babysitting his grandchildren.He gets tired and cannot garden the way he once did. But he is still alive and considers every day a blessing. His experience, and what we see with Biden, shows what living with metastatic prostate cancer can look like today.Understanding survival ratesIf they haven’t asked their doctor already, many patients go online and find five-year survival rates, but every number they may find online comes with a huge asterisk.The American Cancer Society reports five-year relative survival of greater than 99% when prostate cancer is found in or near the prostate. The figure drops to 38% when it has reached distant parts of the body.But that number is based on large groups of men treated years ago. It does not fully reflect the impact of newer treatments — or account for an individual man’s age, overall health and response to therapy.Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live. These patients’ outlook depends on details of their cancer and how they are responding to treatments.It’s treated more aggressively nowA man diagnosed with metastatic prostate cancer a decade ago and a man diagnosed today would not receive the same treatment. The thinking now is to use our best treatments early instead of holding back.For years, doctors began with hormone therapy — usually injections that lower testosterone — and saved other treatments until the cancer stopped responding.Today, those injections are often combined from the start with a newer hormone-blocking drug and/or chemotherapy. These combinations have helped men live longer and are one of the biggest shifts of the past decade.What Biden’s diagnosis told usThere are three details about Biden’s cancer that help doctors like me understand how aggressive it is and how to manage it effectively. Official statements highlighted that his cancer had a Gleason score of 9. The cancer had spread to his bones, and it was labeled as hormone-sensitive.The Gleason score is assigned after a pathologist examines biopsy samples. Scores typically range from 6 to 10, with higher numbers indicating more aggressive cancer. A score of 9 falls into the most aggressive category. However, the score alone cannot tell us whether the cancer has spread outside the prostate.When prostate cancer spreads, the most common destination is the bones — particularly the spine, pelvis and ribs. It can also reach organs such as the lungs or liver. Once it has reached distant parts of the body, it is generally not curable, but treatment can put a brake on it for years.Prostate cancer can also be hormone-sensitive or hormone-resistant. Because it typically relies on testosterone to grow, lowering the hormone or blocking its effects can help control the cancer. Hormone-sensitive means it still responds to these treatments.Over time, most advanced or metastatic prostate cancers find ways to grow despite low testosterone levels, which mean they are now hormone-resistant. Lowering testosterone alone is no longer enough to control the cancer, so doctors have to turn to additional therapies.Knowing if the cancer has spreadThe most sensitive imaging test available today is a PSMA PET scan. It uses a radioactive tracer that seeks out a protein found on the surface of prostate cancer cells. Areas containing cancer may appear as bright spots, helping identify where the cancer has spread. The American Urological Association supports using this imaging test to determine whether high-risk prostate cancer has spread and to help establish its stage.A traditional bone scan, used for decades, highlights areas where bone is reacting to injury or disease. It remains an alternative imaging option, but PSMA PET is increasingly replacing its use.What areas light up and where matter when deciding on treatments. A single spot in the spine and cancer that has spread to the liver are both called stage 4, but they are not the same disease and may not be treated the same way.Doctors also consider how much cancer has spread. We label it as “low-volume” disease when the cancer has reached a limited number of areas. High volume is when the spread is more widespread or has reached other organs such as the liver or lungs.Both require treatment that works throughout the body. Treatment for metastatic disease generally includes therapy that works throughout the body. For men with low-volume disease, adding radiation to the prostate may also help them live longer.Biden has completed a course of radiation, but his team has not disclosed what area was treated or enough detail to determine whether his cancer would be considered low- or high-volume.Treatment has become more preciseBeyond starting more treatments earlier, doctors can increasingly tailor therapy to the biology of an individual man’s cancer. We can now test both the tumor and a patient’s own DNA for mutations that help guide treatment.Roughly 1 in 10 men with metastatic prostate cancer carries an inherited mutation affecting the body’s ability to repair DNA. The best known are BRCA1 and BRCA2, the same genes linked to some breast and ovarian cancers.Certain mutations found in the tumor or inherited DNA may make targeted drugs called PARP inhibitors an option. If a mutation is inherited, it also gives family members information they can act on through genetic counseling, testing and earlier screening.Another advance is radioligand therapy. If a scan shows that cancer cells carry a protein called PSMA, doctors can attach radiation to a molecule that seeks out that protein. Delivered through an IV, it targets cancer cells throughout the body. This approach was expanded last year to more men whose cancer had become hormone resistant.Living longer can come with costsEvery treatment can cause side effects. With hormone therapy, one of the first is often hot flashes, similar to what women experience during menopause. These are not dangerous, but they can affect a man’s quality of life.Fatigue is also common. Testosterone helps maintain muscle, so lowering it can reduce strength and energy. Regular walking and resistance training can help preserve muscle and reduce fatigue.The side effect almost no one talks about is loss of sex drive or low libido. At diagnosis, most men are thinking about staying alive, not their libido. But months later, it often matters. It is worth discussing with your care team and your partner rather than assuming it is simply the price of treatment.The side effect I worry about most is weaker bones. Low testosterone reduces bone density, while cancer deposits can weaken the bone’s structure. Follow-up care should include exercise, a bone-density scan, and ensuring adequate levels of calcium and vitamin D. For men with hormone-resistant cancer that has spread to bone, bone-protecting drugs can reduce the risk of fractures and other complications.New or worsening back pain, especially with leg weakness, numbness or trouble controlling the bladder or bowels? These could mean the cancer is pressing on the spinal cord. It is a true medical emergency that requires immediate attention.Cancer care requires a team approachIdeally, several doctors work together to coordinate a patient’s care. The urologist is often the starting point. A medical oncologist manages treatments that work throughout the body, while a radiation oncologist targets specific areas, whether that is the prostate itself or a painful bone lesion. The primary care doctor helps protect the patient’s heart and bones and looks after the person’s overall health.A man’s age, other medical conditions, ability to tolerate side effects and goals for treatment all shape treatment plans. Two men with nearly identical test results may be offered — or choose — different paths based on their health and priorities.Good communication among doctors is essential, but gaps can happen. Being your own advocate means knowing who is on your care team, asking questions and understanding your options.I also recommend bringing someone you trust to important visits for support and to take notes and help you remember what was discussed.More treatments, better testing offer hopeFor men worried about prostate cancer, talk with your health care provider about the benefits and risks of PSA testing. Black men and those with a strong family history should begin that conversation in their 40s. New urinary symptoms are often not cancer, but they still deserve attention, as does blood in the urine or semen, unexplained weight loss and/or persistent back or bone pain.For men living with advanced prostate cancer, there is reason for hope. There are more treatments and better testing than there were a decade ago, and good care pays attention to how a man feels, not just to what his scans show.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story